cyproheptadine has been researched along with Fibrosis in 2 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ischemic mitral regurgitation (MR) is primarily caused by left ventricle deformation, but leaflet thickening with fibrotic changes are also observed in the valve." | 5.72 | Effects of Cyproheptadine on Mitral Valve Remodeling and Regurgitation After Myocardial Infarction. ( Aikawa, E; Arsenault, M; Beaudoin, J; Clavel, MA; Couet, J; Deschênes, V; Hadjadj, S; Handschumacher, MD; Levine, RA; Marsit, O; Paquin, A; Pibarot, P; Sénéchal-Dumais, I, 2022) |
| "Ischemic mitral regurgitation (MR) is primarily caused by left ventricle deformation, but leaflet thickening with fibrotic changes are also observed in the valve." | 1.72 | Effects of Cyproheptadine on Mitral Valve Remodeling and Regurgitation After Myocardial Infarction. ( Aikawa, E; Arsenault, M; Beaudoin, J; Clavel, MA; Couet, J; Deschênes, V; Hadjadj, S; Handschumacher, MD; Levine, RA; Marsit, O; Paquin, A; Pibarot, P; Sénéchal-Dumais, I, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marsit, O | 1 |
| Clavel, MA | 1 |
| Paquin, A | 1 |
| Deschênes, V | 1 |
| Hadjadj, S | 1 |
| Sénéchal-Dumais, I | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Handschumacher, MD | 1 |
| Levine, RA | 1 |
| Aikawa, E | 1 |
| Pibarot, P | 1 |
| Beaudoin, J | 1 |
| Droogmans, S | 1 |
| Roosens, B | 1 |
| Cosyns, B | 1 |
| Degaillier, C | 1 |
| Hernot, S | 1 |
| Weytjens, C | 1 |
| Garbar, C | 1 |
| Caveliers, V | 1 |
| Pipeleers-Marichal, M | 1 |
| Franken, PR | 1 |
| Lahoutte, T | 1 |
| Schoors, D | 1 |
| Van Camp, G | 1 |
2 other studies available for cyproheptadine and Fibrosis
| Article | Year |
|---|---|
Effects of Cyproheptadine on Mitral Valve Remodeling and Regurgitation After Myocardial Infarction.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cells, Cultured; Cyproheptadine; Fibrosis; | 2022 |
Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study.
Topics: Animals; Blood Pressure; Body Weight; Cyproheptadine; Dopamine Agonists; Drug Interactions; Echocard | 2009 |